Last Updated : September 19, 2024
The latest Reimbursement Review reports are posted to this page. Our Reimbursement Reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
For each drug, plasma product, or cell and gene therapy reviewed in the Drug Reimbursement Review process, there is an opportunity for patient groups and clinician groups to provide input and feedback. See Reimbursement Review Open Calls for Input and Feedback.
Brand Name Sort descending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
---|---|---|---|---|---|---|
Eylea | Aflibercept | Macular edema, branch retinal vein occlusion | Reimburse with clinical criteria and/or conditions | Complete | ||
Eylea | Aflibercept | Macular edema, diabetic | List with clinical criteria and/or conditions | Complete | ||
Eylea | Aflibercept | Macular edema, central retinal vein occlusion | List with clinical criteria and/or conditions | Complete | ||
Eylea HD | aflibercept 8mg/0.07mL | diabetic macular edema | Reimburse with clinical criteria and/or conditions | Active | ||
Eylea HD | aflibercept 8mg/0.07mL | macular degeneration, age related | Reimburse with clinical criteria and/or conditions | Active | ||
Fabrazyme | Agalsidase beta | Fabry Disease | Do not list | Complete | ||
Fabrazyme | Agalsidase beta | Fabry Disease | Do not list | Complete | ||
Fampyra | Fampridine | Multiple sclerosis, improve walking disability | Withdrawn | |||
Fampyra | Fampridine | Multiple sclerosis, improve walking disability | Do not list | Complete | ||
Fasenra | benralizumab | Asthma, severe eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | ||
Fasenra | benralizumab | Asthma, severe eosinophilic | Reimburse with clinical criteria and/or conditions | Complete | ||
Faslodex | Fulvestrant | Locally advanced or metastatic breast cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Fentora | Fentanyl buccal | Pain (breakthrough), cancer (adults) | Do not reimburse | Complete | ||
Ferinject | ferric carboxymaltose | Iron deficiency anemia | Active | |||
Ferinject | ferric carboxymaltose | Iron deficiency in adult patients with heart failure | Active | |||
Ferriprox | deferiprone | Transfusional iron overload | Reimburse with clinical criteria and/or conditions | Complete | ||
Ferriprox | Deferiprone | Transfusional iron overload | List with clinical criteria and/or conditions | Complete | ||
Fibristal | ulipristal acetate | Uterine fibroids (signs and symptoms) | Reimburse with clinical criteria and/or conditions | Complete | ||
Fibristal | ulipristal acetate | Uterine fibroids (signs and symptoms) | Reimburse with clinical criteria and/or conditions | Complete | ||
Fibristal | Ulipristal acetate | Uterine fibroids | List with criteria/condition | Complete | ||
Finacea | Azelaic acid | Rosacea | List | Complete | ||
Firazyr | icatibant | Acute attacks of hereditary angioedema | Canada’s Drug Agency is unable to make a reimbursement recommendation as the manufacturer has not filed a submission. | Not filed | ||
Firazyr | Icatibant | Hereditary angioedema | List with clinical criteria and/or conditions | Complete | ||
Firdapse | amifampridine phosphate | Lambert-Eaton Myasthenic Syndrome, adults | Reimburse with clinical criteria and/or conditions | Complete | ||
Folotyn | Pralatrexate | Peripheral T-Cell Lymphoma (PTCL) | Reimburse with clinical criteria and/or conditions | Complete |